Trial Profile
A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-tenascin monoclonal antibody 81C6 I-131 (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms GLASS-ART
- Sponsors Bradmer Pharmaceuticals
- 05 Nov 2010 Bradmer suspended enrolment of primary GBM patients in its Phase III multi-center clinical trial of Neuradiab in the first quarter of 2009, according to a media release.
- 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 23 Jul 2008 Status changed to recruiting. Bradmer reports that the first patient was enrolled at Duke University.